ZA200402989B - Stents. - Google Patents
Stents. Download PDFInfo
- Publication number
- ZA200402989B ZA200402989B ZA200402989A ZA200402989A ZA200402989B ZA 200402989 B ZA200402989 B ZA 200402989B ZA 200402989 A ZA200402989 A ZA 200402989A ZA 200402989 A ZA200402989 A ZA 200402989A ZA 200402989 B ZA200402989 B ZA 200402989B
- Authority
- ZA
- South Africa
- Prior art keywords
- stents
- formula
- compounds
- radical
- stent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000004480 active ingredient Substances 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 208000037803 restenosis Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 208000007536 Thrombosis Diseases 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- -1 nitro, amino Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 240000000662 Anethum graveolens Species 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 150000001204 N-oxides Chemical class 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 108010074860 Factor Xa Proteins 0.000 description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 206010038563 Reocclusion Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001693 poly(ether-ester) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940028869 ticlid Drugs 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/04—Use of organic materials, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10152460A DE10152460A1 (de) | 2001-10-24 | 2001-10-24 | Stents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402989B true ZA200402989B (en) | 2005-04-20 |
Family
ID=7703557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402989A ZA200402989B (en) | 2001-10-24 | 2004-04-20 | Stents. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20050064006A1 (fr) |
| EP (1) | EP1439869A1 (fr) |
| JP (1) | JP2005506151A (fr) |
| KR (1) | KR20040074977A (fr) |
| CN (1) | CN1575189A (fr) |
| AU (1) | AU2002340549B2 (fr) |
| BR (1) | BR0213481A (fr) |
| CA (1) | CA2464290A1 (fr) |
| DE (1) | DE10152460A1 (fr) |
| EC (1) | ECSP045075A (fr) |
| EE (1) | EE200400080A (fr) |
| HR (1) | HRP20040456A2 (fr) |
| HU (1) | HUP0401760A3 (fr) |
| IL (1) | IL161445A0 (fr) |
| MA (1) | MA26341A1 (fr) |
| MX (1) | MXPA04003755A (fr) |
| NO (1) | NO20041984L (fr) |
| NZ (1) | NZ532443A (fr) |
| PL (1) | PL367968A1 (fr) |
| RU (1) | RU2004115757A (fr) |
| WO (1) | WO2003035133A1 (fr) |
| ZA (1) | ZA200402989B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| EP1685841A1 (fr) * | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention et traitement de troubles thromboemboliques |
| DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| PT1934208E (pt) | 2005-10-04 | 2011-06-01 | Bayer Schering Pharma Ag | Nova forma polimorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3- oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2- tiofenocarboxamida |
| DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
| US20070097252A1 (en) * | 2005-10-31 | 2007-05-03 | Silverstein D A | Imaging methods, cameras, projectors, and articles of manufacture |
| DE102006034916A1 (de) * | 2006-07-28 | 2008-01-31 | Bayer Healthcare Ag | Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten |
| DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| WO2009063028A2 (fr) * | 2007-11-15 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Amides substitués, leur fabrication et utilisation sous forme de médicaments |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0623615B1 (fr) * | 1993-05-01 | 1999-06-30 | MERCK PATENT GmbH | Dérivés de 1-phényl-oxazolidin-2-one substitués, leur préparation et leur utilisation comme antagonistes du récepteur d'adhésion |
| WO1998046628A1 (fr) * | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | INHIBITEURS SELECTIFS DU FACTEUR Xa |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US20010029351A1 (en) * | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
| DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10105989A1 (de) * | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
-
2001
- 2001-10-24 DE DE10152460A patent/DE10152460A1/de not_active Withdrawn
-
2002
- 2002-02-11 IL IL16144502A patent/IL161445A0/xx unknown
- 2002-10-11 CA CA002464290A patent/CA2464290A1/fr not_active Abandoned
- 2002-10-11 EE EEP200400080A patent/EE200400080A/xx unknown
- 2002-10-11 RU RU2004115757/15A patent/RU2004115757A/ru not_active Application Discontinuation
- 2002-10-11 AU AU2002340549A patent/AU2002340549B2/en not_active Ceased
- 2002-10-11 CN CNA028210034A patent/CN1575189A/zh active Pending
- 2002-10-11 EP EP02774699A patent/EP1439869A1/fr not_active Withdrawn
- 2002-10-11 MX MXPA04003755A patent/MXPA04003755A/es not_active Application Discontinuation
- 2002-10-11 PL PL02367968A patent/PL367968A1/xx not_active Application Discontinuation
- 2002-10-11 JP JP2003537695A patent/JP2005506151A/ja active Pending
- 2002-10-11 US US10/493,552 patent/US20050064006A1/en not_active Abandoned
- 2002-10-11 WO PCT/EP2002/011402 patent/WO2003035133A1/fr active IP Right Grant
- 2002-10-11 HU HU0401760A patent/HUP0401760A3/hu unknown
- 2002-10-11 BR BR0213481-0A patent/BR0213481A/pt not_active IP Right Cessation
- 2002-10-11 KR KR10-2004-7006051A patent/KR20040074977A/ko not_active Application Discontinuation
- 2002-10-11 NZ NZ532443A patent/NZ532443A/en unknown
-
2004
- 2004-04-20 ZA ZA200402989A patent/ZA200402989B/en unknown
- 2004-04-22 EC EC2004005075A patent/ECSP045075A/es unknown
- 2004-04-23 MA MA27648A patent/MA26341A1/fr unknown
- 2004-05-13 NO NO20041984A patent/NO20041984L/no not_active Application Discontinuation
- 2004-05-21 HR HR20040456A patent/HRP20040456A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL161445A0 (en) | 2004-09-27 |
| MXPA04003755A (es) | 2004-07-23 |
| EE200400080A (et) | 2004-08-16 |
| JP2005506151A (ja) | 2005-03-03 |
| PL367968A1 (en) | 2005-03-07 |
| CN1575189A (zh) | 2005-02-02 |
| HUP0401760A3 (en) | 2008-04-28 |
| MA26341A1 (fr) | 2004-10-01 |
| CA2464290A1 (fr) | 2003-05-01 |
| HUP0401760A2 (hu) | 2004-12-28 |
| DE10152460A1 (de) | 2003-05-08 |
| RU2004115757A (ru) | 2005-04-10 |
| US20050064006A1 (en) | 2005-03-24 |
| HRP20040456A2 (en) | 2005-06-30 |
| AU2002340549B2 (en) | 2007-11-29 |
| WO2003035133A1 (fr) | 2003-05-01 |
| ECSP045075A (es) | 2004-05-28 |
| NZ532443A (en) | 2005-11-25 |
| BR0213481A (pt) | 2004-11-03 |
| KR20040074977A (ko) | 2004-08-26 |
| NO20041984L (no) | 2004-05-13 |
| EP1439869A1 (fr) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7799335B2 (en) | Differential delivery of nitric oxide | |
| AU2002340549B2 (en) | Stents | |
| US8679520B2 (en) | Coating of stents for preventing restenosis | |
| EP1808167B1 (fr) | Articles d'élution de médicaments avec profils de distribution de médicaments améliorés | |
| CN101940802B (zh) | 药物缓释性支架 | |
| US20050043788A1 (en) | Drug-eluting stent | |
| JP2001190687A (ja) | ステント及びステントグラフト | |
| AU2003283399B2 (en) | Drug delivery system | |
| US20080199506A1 (en) | Coating of the Entire Surface of Endoprostheses | |
| MXPA04008361A (es) | Stents recubiertos con n-{5 -[4-(4- metil-piperazino- metil)- benozilamido]- 2-metilfenil} -4-(3- piridil) -2- pirimidin- amina. | |
| PT1699503E (pt) | Dispositivos revestidos com polímeros do tipo pec | |
| CA2559756A1 (fr) | Stent recouvert d'un inhibiteur de la tyrosine kinase du recepteur vegf | |
| US20050175667A1 (en) | Use of endothelin antagonists to prevent restenosis | |
| WO2014125465A2 (fr) | Procédé pour ajouter une charge à des ballonnets de cathéters dilatables et cathéters de dilatation ainsi obtenus | |
| JP2009524501A (ja) | 水溶性薬剤の放出遅延用薬剤送達システム | |
| JP2007508039A (ja) | 生体適合性および生物学的安定性を有する医療用品表面コーティング | |
| AU2011329270B2 (en) | Local vascular delivery of an adenosine A2A receptor agonist / phosphodiesterase inhibitor combination to reduce myocardial injury | |
| CA2453977A1 (fr) | Stents contenant des antagonistes du recepteur de la vitronectine utilises pour traiter la restenose | |
| PL236142B1 (pl) | Sposób wytwarzania z układu kopolimer-inhibitor szlaku mTOR powłoki o kontrolowanej kinetyce uwalniania inhibitora szlaku mTOR na polimerowych stentach naczyniowych |